



Revolutionizing Cellular Therapies for Cancer and Beyond

Building a Discovery-to-Clinic Company to Exploit the Full Power of Cell Therapies

Ian Nisbet, PhD
Chief Operating Officer

3rd ANZ Biologics Festival
04 February 2025

Acknowledgement Of Traditional Owners

In the spirit of reconciliation, Cartherics acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.

Forward Looking Statements

This presentation contains forward-looking statements within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements do not relate strictly to historical or current facts and may be accompanied by words such as 'could,' 'would,' 'may,' 'potentially,' 'suggest,' 'believes,' 'expects,' 'should,' 'intends,' 'plans,' 'forecasts,' and similar words or expressions.

Such statements involve substantial risks and uncertainties, not all of which may be known at the time. All statements contained in this presentation, other than statements of historical fact, including without limitation statements regarding our strategy, research and development plans, collaborations, future operations, future financial position, future revenues, projected costs, pricing, prospects, plans, and objectives of management, are forward-looking statements. Not all forward-looking statements in this presentation are explicitly identified as such.

The Company does not warrant any of the forward-looking statements in this presentation, and investors are advised to interpret such statements in the context of other available sources of information and with the assistance of expert advisors as appropriate.

Many factors could cause the actual results of the Company to differ materially from the results expressed or implied herein, and you should not place undue reliance on the forward-looking statements. Drug development is inherently risky, and only a small proportion of research and development programs lead to a marketed product. Factors which could change the Company's expected outcomes include, without limitation, our ability to: advance the development of our programs, and to do so within any timelines

that may be indicated herein; the safety and efficacy of our drug development candidates; our ability to replicate experimental data; the ongoing validity of patents covering our drug development candidates, and our freedom to operate under third party intellectual property; our ability to obtain necessary regulatory approvals; our ability to enter into and maintain partnerships, collaborations, and other business relationships necessary to the progression of our drug development candidates; changes in the competitive landscape pertaining to our drug development candidates; the timely availability of necessary capital to pursue our business objectives; changes in the public policy environment in one or more countries in which we operate or may seek to operate which disfavours our business; our ability to attract and retain qualified personnel; changes from anticipated levels of customer acceptance of existing and new products and services; and other factors, including the COVID-19 pandemic and the conflict in Ukraine.

Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, and although they reflect our current views as at the date of this presentation, there can therefore be no assurance that such expectations will prove to be correct. The Company has no obligation as a result of this presentation to pursue any specific strategy or plan outlined herein, or to deliver any specific outcome that may be implied or inferred.

Any forward-looking statements contained in this presentation speak only as of the date this presentation is made, and we expressly disclaim any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.

One Year Ago

Rearming the immune system to fight cancer

External Environment:

- Subdued investor / pharma interest in cell therapies
- Lay-offs and program cuts by cell therapy companies
- Increasing momentum with alternative approaches in oncology
 - Antibody drug conjugates
 - Bispecific antibodies
 - Radiopharmaceuticals

Internal Situation:

- Successful pre-IND meeting for CTH-401 in ovarian cancer
- Preparing for tech transfer of CTH-401 manufacturing to CMO
- Requirement for additional capital
- ANZ Biologics Festival – know when to hold-em, know when to fold-em

Fast Forward to 2025

Revolutionizing Cellular Therapies for Cancer and Beyond

External Environment:

- Ongoing subdued investor / pharma interest in cell therapies
- Ongoing redundancies and program cuts by cell therapy companies, plus a shift to non-cancer indications
- Ongoing momentum for alternative approaches in oncology
 - Antibody drug conjugates
 - Bispecific antibodies
 - Radiopharmaceuticals

Internal Situation:

- \$A20M financing completed
- Shift from CMO to internal clinical manufacturing for CTH-401
- IND filing in 2025
- Bigger / bolder vision to drive ongoing funding
- ANZ Biologics Festival – know when to double down?



Revolutionizing Cellular Therapies for Cancer and Beyond


Cartherics
uses the *full power*
of its cell therapy platform to
develop novel therapies

that attack cancers
where chemotherapy and other
treatments fail; *and*

*offer new approaches to
the treatment of other
intractable diseases, such
as endometriosis and
neuroinflammatory
conditions*

Cartherics Cell Therapy Platform

Enables the rapid development of a diverse range of products and immune cell types



Leveraging the Platform to Expand into Extracellular Vesicles (EVs)

EVs offer advantages where other/cell therapies faces challenges

Production and Distribution:

- Leverages used medium from cell production
- Utilises established, scalable purification procedures
- No requirement for cryopreservation
- Storage and distribution more akin to a drug than a cell

Therapeutic Use:

- Reduced risk of toxicity
- Non-immunogenic
- Potential for enhanced tumor penetration and less negative impact of TME in cancer indications
- Potential for targeting to specific organs (e.g., brain)
- Potential to add therapeutic cargo



Revolutionizing Cellular Therapies for Cancer and Beyond

Cartherics uses the full power
of its cell therapy platform to
develop novel therapies



**that attack cancers where
chemotherapy and other
treatments fail**

Lead Product Candidate: CTH-401

First TAG-72 CAR-NK cell therapy

iPSCs gene-edited using CRISPR/Cas9

- **TAG-72 CAR knock-in**
 - Complements normal NK cell killing functions
- **Immunosuppressive gene knock-outs**
 - Enhance anti-tumoral efficacy
- **KI and KOs validated in autologous CAR-T cells**




Tumor-associated glycoprotein-72 (TAG-72)

- Well-validated tumor target
- Found on many adenocarcinomas, including ovarian, gastric, colorectal, pancreatic cancers


Image: Ovarian cancer biopsy with TAG-72 staining (brown) by immunohistochemistry

CTH-401: Proven Efficacy Against Ovarian Cancer in Mice




Cancer shown in blue-red increasing

CTH-401 TAG-72 CAR and gene KO enhance and prolong anti-tumor activity




*Luciferase-labeled OVCAR-3 cells administered i/p on D-4; NK cells administered on D0 (E:T ratio 50:1); bioluminescence monitored weekly and normalized to D-1 signal; median fold-change in luminescence (Arbitrary Units) is shown through to study termination (D84).

In-House Manufacturing of CTH-401



CTH-401: Clear, De-Risked Path to First-in-Human Trials





Revolutionizing Cellular Therapies for Cancer and Beyond

Cartherics uses the full
power of its cell therapy platform
to develop novel therapies

**that offer new approaches
to the treatment of other intractable
diseases, such as endometriosis
and neuroinflammatory
conditions**

Expanding into Non-Oncology Indications

Cartherics is exploring novel, high-value applications for its cellular immunotherapy platform, distinguishing itself from key competitors

Safety profile of NK cells or EVs make them ideal candidates for non-oncology indications

Emerging evidence for low levels of and/or defective NK cells playing a role in diseases such as:

- Endometriosis
- Alzheimer's Disease
- Traumatic Brain Injury



2025 and Beyond

Positioning the company for growth and value creation

Cartherics raised ~A\$20M in 2024 to fund the final stages of IND filing for CTH-401 and commencement of clinical trials in 2025/26

The Company intends to raise new funds in 2025 in association with exploring a public listing

These funds will be used for:

- Completion of CTH-401 Phase I/II clinical trial in ovarian cancer
- Scale-up of product manufacturing
- Pre-clinical development of CTH-501 (TF CAR-NK) in triple negative breast cancer and endometriosis
- Proof-of-concept for NK cell and EV products in neuroinflammatory conditions